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Abstract Clostridium perfringens is a cause for increasing
concern due to its responsibility for severe infections both in
humans and animals, especially poultry. To find new control
strategies to treat C. perfringens infection, we investigated the
activity and delivery of a bacteriophage endolysin. We iden-
tified a new endolysin, designated CP25L, which shows sim-
ilarity to anN-acetylmuramoyl-L-alanine amidase domain and
is distinct from other C. perfringens endolysins whose activity
has been demonstrated in vitro. The cp25l gene was cloned
and expressed in Escherichia coli, and the gene product
demonstrated lytic activity against all 25C. perfringens strains
tested. The probiotic strain Lactobacillus johnsonii FI9785
was engineered to deliver the endolysin to the gastrointestinal
tract. The integration of the nisRK two-component regulatory
system from the Lactococcus lactis nisin A biosynthesis op-
eron into the chromosome of L. johnsonii allowed constitutive
expression of the endolysin under the control of the nisA
promoter (PnisA), while the use of a signal peptide (SLPmod)
led to successful secretion of the active endolysin to the
surrounding media. The high specificity and activity of the
endolysin suggest that it may be developed as an effective tool
to enhance the control of C. perfringens by L. johnsonii in the
gastrointestinal tract.
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Introduction
Clostridium perfringens is a rod-shaped, Gram-positive, an-
aerobic spore-forming bacterium with the ability to produce
potent toxins. According to the pattern of toxin expression, C.
perfringens strains are classified into five toxinotypes: A, B,
C, D, and E (Miyamoto et al. 2012; Petit et al. 1999). The
interest in this microorganism is increasing because it is re-
sponsible for a range of debilitating conditions, including food
poisoning, gas gangrene, necrotic enteritis (NE) both in
humans and animals, and non-food-borne gastrointestinal in-
fections (Keyburn et al. 2008; Lindstrom et al. 2011). C.
perfringens associated food poisoning is classed among the
most common gastrointestinal diseases in industrialized coun-
tries (Lindstrom et al. 2011; Scallan et al. 2011). One of the
most frequently occurring infections caused byC. perfringens
type A is NE in poultry; in countries where the use of antimi-
crobial growth promoters in feed has been abolished, the
incidence of NE has increased, and the productivity of the
poultry industry has been reduced (Lee et al. 2011; Van
Immerseel et al. 2009). A range of different alternatives to
the conventional antimicrobial growth promoter approach are
being investigated to reduce the numbers of these pathogens
in the food chain and improve poultry health. In addition to
vaccination (Lee et al. 2011) or the use of natural antimicro-
bials (Timbermont et al. 2010), there are a number of exam-
ples of using probiotic microbes (Gil de los Santos et al. 2012;
Kizerwetter-Swida and Binek 2009; La Ragione et al. 2004)
or lytic enzymes (Liu et al. 2010; Zhang et al. 2010) to control
NE in poultry. Bacteriophages and their endolysins present a
further opportunity to reduce C. perfringens without
disturbing the balance of the microbiota in the gastrointestinal
(GI) tract.
Bacteriophage therapy is a rapidly growing area of research
(Lu et al. 2011; O'Flaherty et al. 2009), and tests in poultry
have demonstrated the potential of bacteriophages to control
levels of C. perfringens, Salmonella, and Campylobacter
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(Atterbury et al. 2007; El-Shibiny et al. 2009; Miller et al.
2010). However, the narrow host range of bacteriophages and
the rapid development of resistance can limit their application
as control agents. An alternative approach is to develop bac-
teriophage proteins as novel antimicrobial agents. At the end
of their lytic cycle, most dsDNA bacteriophages release their
progeny by lysis of the host cell via the activity of two
proteins—the holin and the endolysin. The holins are small
hydrophobic proteins which disrupt the cell membrane to
produce holes, allowing the endolysin to access the cell wall
(Catalao et al. 2012). The endolysins target bonds in the
peptidoglycan, resulting in the destruction of the cell and the
release of newly produced virions. Although evolved to act
from inside the cell, endolysins which act on Gram-positive
bacteria are also effective when applied exogenously, giving
them the potential to be used as targeted antibacterial agents
(Fischetti 2010).
Although there are several variations in endolysin architec-
ture, the majority of endolysins from bacteriophages infecting
Gram-positive bacteria consist of two functional regions: the
enzymatically active region contains one or more domains
providing the catalytic activity of the enzyme (e.g.,
muramidase, glucosaminidase, endopeptidase, or amidase),
attacking specific bonds in the peptidoglycan, while the cell
wall binding region allows the endolysin to bind to specific
ligands found in the cell wall of the host bacterium and so
provides specificity (Schmelcher et al. 2012). Properties such
as this specificity for their host pathogen, leading to minimal
disturbance of the normal flora, the low risk of bacterial
resistance, and the ability to kill colonizing pathogens on
mucosal surfaces make them ideal anti-infective agents
(Fischetti 2010; O’Flaherty et al. 2009). Recent studies dem-
onstrated the efficiency of endolysins in killing or controlling
pathogenic bacteria in animal models (Fenton et al. 2010;
Grandgirard et al. 2008; Gupta et al. 2011; Yoong et al.
2006); they have also shown efficacy against biofilms
(Meng et al. 2011), as disinfectants (Hoopes et al. 2009) and
as the basis of detection systems for bacteria (Kretzer et al.
2007). Several bacteriophage endolysins which produce lytic
activity against C. perfringens cells have been described
(Nariya et al. 2011; Schmitz et al. 2011; Simmons et al.
2010; Zimmer et al. 2002). A number have also been identi-
fied by sequencing and genome mining, producing a rich
resource of information for such enzymes (Morales et al.
2012; Oakley et al. 2011; Schmitz et al. 2011; Volozhantsev
et al. 2012; Volozhantsev et al. 2011).
Lactobacillus johnsonii FI9785 is a poultry-isolated strain
which has been shown to act as a competitive exclusion agent
against C. perfringens in chickens (La Ragione et al. 2004).
As well as acting as probiotics in their own right, lactic acid
bacteria have also shown promise as delivery systems for the
secretion of biologically active interleukins or peptidoglycan
hydrolases (Braat et al. 2006; Fernandez et al. 2009; Turner
et al. 2007). The promoter of the structural gene encoding the
lantibiotic nisin A (PnisA) is induced by nisin A via signal
transduction using the two component regulatory system
NisRK (Kuipers et al. 1995). This system has been exploited
to develop gene expression systems in Lactococcus lactis,
Leuconostoc lactis, and Lactobacillus helveticus (de Ruyter
et al. 1996; Kleerebezem et al. 1997), and in this study, we
have used the NisRK system to express the endolysin CP25L,
originating from a prophage of C. perfringens (Gervasi et al.
2013), in a probiotic strain of L. johnsonii which was
engineered for delivery to the GI tract.
Materials and methods
Bacterial strains and growth conditions
C. perfringens strains (listed in Table 1) were obtained from
the NCTC (HPA, London, UK), or from in-house culture
collections (IFR, Norwich, UK). C. perfringens 5416–97 is
a type A strain (Grant et al. 2008). Strains were maintained in
Robertson’s cooked-meat medium (SGL) at room temperature
and were grown anaerobically at 37 °C in brain heart infusion
broth (BHI, Oxoid) supplemented with vitamin K [50 μg/l],
hemin [5 mg/l], resazurin [1 mg/l], and L-cysteine [0.5 g/l]),
termed BHI+C. Escherichia coli strains were grown in L
broth with shaking at 37 °C, and L. johnsonii strain FI9785
(NCIMB 41621) (La Ragione et al. 2004) and derivatives
were grown in MRS broth (Oxoid) at 37 °C. Commensal,
environmental, and clostridial strains (listed in Tables 1 and 2)
were obtained from IFR culture collections, the DSMZ
(Braunschweig, Germany), or the NCIMB (Aberdeen, UK)
and were grown as recommended by DSMZ or in BHI+C.
Endolysin CP25L analysis and subcloning
The endolysin sequence is available in the vB_CpeS-CP51
genome nucleotide sequence, accession number KC237729.
Endolysin amino acid similarities and conserved domains
were determined using Blastp (Altschul et al. 1997) and the
NCBI non-redundant protein sequences database. Amino acid
alignments were performed using the ClustalW algorithm in
Vector NTI (Invitrogen) and visualized with GeneDoc
(Nicholas et al. 1997).
Genomic DNAwas extracted from cells of C. perfringens
5416–97 (grown to mid-exponential phase) using the
Genomic DNA extraction kit with a Genomic Tip 20/G col-
umn (Qiagen) as described by the manufacturer, with the
addition of 50 U mutanolysin (Sigma) to aid cell lysis. The
putative endolysin gene cp25l was amplified from genomic
DNA using Phusion DNA polymerase (Finnzymes). To facil-
itate cloning into the NdeI and XhoI sites of expression vector
pET15b (Novagen), primers were designed to incorporate an
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NdeI site at the initiating methionine codon CP25L_NDE (5’-
GAATGTCATATGTATATAAATCAATCA-3’, altered nucle-
otides underlined throughout) and a XhoI site downstream of
the stop codon CP25L_XHO (5’-ACTCGAGGTGGGATAA
TTCCTACC-3’). Due to the presence of an internal NdeI site,
internal primers were designed to create a 1 bp substitution
(T771C) without changing the resulting amino acid sequence.
Primer CP25L_GTG (5’-TATTGCATGTGGTAGTCAA
AAGAT-3’) was used in conjunction with CP25L_NDE, and
primer CP25L_CAC (5’-TTGACTACCACATGCAATATAA
AAATG-3’) was paired with CP25L_XHO, then the two
products were spliced and amplified using overlap extension
polymerase chain reaction (Horton et al. 1989) with primers
CP25L_NDE and CP25L_XHO. The spliced product was
restricted with NdeI and XhoI (New England Biolabs) and
cloned into restricted pET15b that had been dephosphorylated
with Antarctic Phosphatase (New England Biolabs), using
Fastlink ligase (Epicentre). Ligation products were transformed
into chemically competent E. coli TOP10 cells (Invitrogen),
and transformants were selected with ampicillin (100 μg/ml).
After confirmation by sequencing, construct pET15b-cp25l
and the empty control vector pET15b were transformed for
expression into chemically competent E. coli BL21(DE3) cells
(Invitrogen).
Table 1 Lytic activity of CP25L against sensitive strains
Lytic activitya
Bacterial strains CP25L Lag (min) Lysozyme
C. perfringens NCTC 3110 79.5±1.0 1 –
C. perfringens NCTC 8238 59.2±0.9 6 21.8±1.5
C. perfringens NCTC 8239 28.6±0.4 6 10.6±0.6
C. perfringens 5146-97b 58.8±4.4 4 8.5±0.5
C. perfringens 5810-97b 17.1±2.5 10 5.6±0.9
C. perfringens 2144-98b 39.8±3.1 10 22.5±0.0
C. perfringens 2118-98b 23.0±0.2 – 16.7±0.4
C. perfringens 2536-01b 44.6±0.7 2 30.2±0.6
C. perfringens 2551-01b 50.7±1.7 4 25.4±1.0
C. perfringens 4519-98b 70.5±1.7 8 15.6±0.1
C. perfringens 2151-88b 34.2±0.4 – 17.5±0.8
C. perfringens 6081-97b 38.0±0.7 – 16.7±0.0
C. perfringens 3011-98b 38.8±0.3 – 22.0±0.0
C. perfringens 2540598b 37.9±0.6 8 –
C. perfringens F3278 39.4±1.2 15 20.2±2.7
C. perfringens N151/151 49.4±2.0 – 9.8±0.3
C. perfringens N147/155A 46.4±2.3 4 7.3±0.0
C. perfringens DP2 39.4±2.1 6 –
C. perfringens DP3 35.7±0.0 – 24.3±0.0
C. perfringens DP5 46.2±1.8 – 15.7±0.4
C. perfringens CH1 37.5±5.9 4 –
C. perfringens CH2 35.4±0.2 6 –
C. perfringens FD00389c 26.5±9.7 22 –
C. perfringens FD00413c 37.8±0.5 – –
C. perfringens FD00412c 5.5±0.2 6 –
B. cereus NCIMB 11796 17.3±1.3 6 46.7±1.5
B. subtilis ATCC 6633 5.5±2.5 6 –
C. acetobutylicum BL75141 9.5±0.3 18 33.2±1.3
C. bifermentans NCTC 13019 56.6±0.5 4 –
C. beijerinckii NCIMB 8052 13.5±2.3 6 46.6±1.0
a Percent drop in OD600 in 4 min linear lysis (mean±standard deviation),
dash no lysis/lag
b Strains kindly provided by Dr. M. Brett, (HPA, UK)
c Strains kindly provided by Prof. R La Ragione (AHVLA, UK)
Table 2 Strains resistant to lysis by CP25L
Bacterial strains
Anaerococcus hydrogenalis DSMZ 7454
Bacillus amyloliquefaciens 0880
Bifidobacterium adolescentis DSMZ 20083
Bifidobacterium angulatum DSMZ 20098
Bifidobacterium bifidum DSMZ 20082
Bifidobacterium longum DSMZ 20219
Bifidobacterium pseudocatenulatum DSMZ 20438
Clostridium cellobioparum DSMZ 1351
Clostridium coccoides NCTC 11035
Clostridium colinum DSMZ 6011
Clostridium difficile NCTC 11204
Clostridium innocuum DSMZ 1286
Clostridium leptum DSMZ 753
Clostridium nexile DSMZ 1787
Clostridium ramosum DSMZ 1402
Clostridium sordellii NCTC 13356
Clostridium sporogenes ATCC 17886
Clostridium tyrobutyricum NCIMB 9582
Enterococcus faecalis FI10734
Enterococcus hirae FI10477






Leuconostoc mesenteroides subsp. mesenteroides ATCC 8293
Listeria innocua NCTC 11288




Salmonella enterica serovar Typhimurium FI10739
Salmonella enterica serovar Enteritidis FI10113
S. aureus FI10139
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An endolysin expression and secretion construct was pro-
duced in pUK200 (Wegmann et al. 1999) placing the endolysin
coding sequence downstream of the signal peptide SLPmod
(Fernandez et al. 2009), and a 6xHis tag, all under the control of
the promoter PnisA (pUK200-slpmod-6xHis-cp25l). Ligation
products were transformed into electrocompetent E. coli
MC1022, selected with chloramphenicol (15 μg/ml) and con-
firmed by sequencing. To provide the two-component regula-
tory system required for PnisA-controlled expression, the nisRK
genes from L. lactis FI5876 (Dodd et al. 1992) were inserted
into the chromosome of L. johnsonii FI9785 using the
thermosensitive pG+host9 vector (Maguin et al. 1996). An
integration region was amplified from L. johnsonii FI9785
genomic DNA, and the resulting 1,033-bp product was cloned
into the blunt-ended SpeI site of pG+host9 (creating plasmid
pFI2657). A 2.4-kb region encoding nisRKwas amplified from
the genome of L. lactis FI5876 using the primer pair nisRK_F
(5’-CCCGGGAGAATCTTAAAGAGTCTAGGG-3’) and
nisRK_R (5’-AAAAAGTAATCCTTAGAGATTAC-3’) and
cloned into a blunt-ended BstEII site located within the inte-
gration region of pFI2657, creating pFI2652. Subsequently,
L. johnsonii FI9785 was transformed with pFI2652, and the
nisRK sequences were integrated into the chromosome by gene
replacement (Maguin et al. 1996) using 30 °C as the permissive
temperature and 42 °C as the non-permissive temperature, to
create the nisRK-carrying strain FI10744. The lysin expression
construct and the control vector pUK200were transformed into
electrocompetent L. johnsonii FI10744 as described (Horn
et al. 2005), and positive transformants were selected using
chloramphenicol (7.5 μg/ml) to give the endolysin delivery
strain FI10744-L and the vector control FI10744-V.
Protein expression, analysis, and partial purification
Crude protein extracts were produced from IPTG-induced
E. coli BL21(DE3) cells containing pET15b-cp25l or
pET15b in NP buffer (20 mM sodium phosphate buffer
pH 6.5) as previously described (Mayer et al. 2008). His-
CP25L was purified using the nickel-nitrilotriacetic acid (Ni-
NTA) Fast Start kit (Qiagen). For expression in L. johnsonii,
cells were grown to mid-exponential phase then incubated for
2 h with or without nisin (10 ng/ml). Cells were harvested by
centrifugation for 10 min at 2,500×g and 4 °C, and the cell
pellet was frozen while the supernatant was concentrated 20-
fold using Amicon columns (Ultra-4 ultracell-30 k, Millipore)
or 166-fold by shaking for 5 min after the addition of an equal
volume of 100 % ethanol pre-cooled to −80 °C, followed by
centrifugation for 30 min at 10,000×g and 4 °C. The resulting
pellet was freeze-dried prior to resuspension in Ni-NTA elu-
tion buffer (EB, 50 mM sodium phosphate, 300 mM NaCl,
250 mM imidazole pH 8). Crude cell extracts were produced
in EB by bead beating as with E. coli. Protein quantification,
electrophoresis, and Western blot analysis with a His Tag®
monoclonal antibody (Novagen) were all performed as de-
scribed previously (Mayer et al. 2008).
Lysis assays
The lysis of C. perfringens NCTC 3110 cells resuspended in
phosphate-buffered saline (PBS) was assessed by turbidity reduc-
tion assay as previously described (Mayer et al. 2008) in duplicate
300-μl assays comprising 270 μl resuspended cells and 30 μl
crude or Ni-NTA purified endolysin extract or the appropriate
buffer controls. Cells for lysis assays were harvested by centrifu-
gation, flash-frozen in liquid nitrogen, and stored at −20 °C until
use. Hen egg white lysozyme (Sigma) was used as a positive
control at 500 U per 300 μl assay. The activity in different media
was assessed by replacing the PBS with BHI+C or chemostat
medium, a complexmedium used for in vitro fermentations (CM:
peptone water 2 g/l (Oxoid), yeast extract 2 g/l (Oxoid), NaCl
0.1 g/l, K2HPO4 0.04 g/l, KH2PO4 0.04 g/l, MgSO4.7H2O 0.01
g/l, CaCl2.6H2O 0.01 g/l, NaHCO3 2 g/l, Tween 80 2 ml, hemin
0.02 g/l dissolved in 400 μL 1 M NaOH, vitamin K1 10 μl of
5 %v/v aqueous solution, cysteine HCl 0.5 g/l, bile salts 0.5 g/l,
and 1 % glucose all from Sigma (Mandalari et al. 2007)), which
was adjusted to pH 6 to approximate colon conditions. Activity
against different species was assessed using 1 μg of Ni-NTA
purified protein during a 1-h incubation. The endolysin activity
of crude protein extracts and concentrated culture supernatants
from the engineered L. johnsonii strains was measured by plate
assay as described previously (Stentz et al. 2010).
Briefly, C. perfringens cells were grown to stationary phase
in 100 ml BHI broth, autoclaved, pelleted by centrifugation
then resuspended in 1 ml of PBS, and added to 100 ml of PBS
with 1 % agar at 55 °C. After pouring into plates, small holes
were punched into the seeded agar, and 10μl of protein extract
(equivalent to 30 μg total crude protein) or 20 μl of concen-
trated supernatants was loaded into the wells, and the plates
were then incubated for 24 h at 37 °C. To demonstrate lytic
activity from growing colonies, C. perfringens cells were
processed in the same way then incorporated into plates
containing MRS agar with 7.5 μg/ml chloramphenicol.
Overnight cultures of FI10744-L and FI10744-V were subse-
quently streaked onto these plates, and the plates were incu-
bated for 1–3 days at 37 °C.
C. perfringensNCTC 3110 viability assays were performed
by adding 166μg of Ni-NTA purified CP25L protein to 5ml of
pre-reduced BHI+C under anaerobic conditions. The
protein was added to the media either immediately
before C. perfringens inoculation (20 μl of a fresh overnight
culture) or during the early exponential phase of growth
(optical density [OD600] ca. 0.3). To determine C. perfringens
viability, samples were taken every 2 h for 8 h and serially
diluted in PBS before being plated onto BHI agar and incu-
bated for 24 to 48 h at 37 °C. Results were calculated as the
total number of bacteria from triplicate counts.
2498 Appl Microbiol Biotechnol (2014) 98:2495–2505
Results
Bioinformatic analysis of the CP25L sequence
The cp25l gene was identified previously within the genome
of a mitomycin C-inducible prophage ofC. perfringens 5416–
97, vB_CpeS-CP51 (Gervasi et al. 2013). Blastp analysis of
CP25L identified two regions with similarity to conserved
domains separated by a central section (Fig. 1). In the N-
terminal part of the protein, there is an area with similarity to
domains associated with cell wall binding and lysis, including
the peptidoglycan recognition protein (PGRP, cd06583, ami-
no acids 19–135, E value 1.24e-23), lysozyme (PHA00447,
amino acids 22–134, E value 3.62e-25) and amidase_2 (N-
acetylmuramoyl-L-alanine amidase, pfam01510, amino acids
20–128, E value 2.37e-22). An area with similarity to a
bacterial SH3 domain (SH3_3, pfam08239, amino acids
322–375, E value 4.14e-09) is located at the C terminus.
Alignments of this protein with other C. perfringens
endolysins whose activity has been demonstrated experimen-
tally revealed that there are only very low levels of amino acid
conservation with the amidase_3 domain-containing lysins
ply3626 (Zimmer et al. 2002) (28 % consensus/14.7 % iden-
tity), plyCP26F, or plyCP39O (Simmons et al. 2010) (14.1 %/
7.4 % and 13.5 %/7.7 %, respectively), or with the glycosyl
hydrolase_25 domain-containing Pms (Nariya et al. 2011)
(26.3 %/16.3 %) or PlyCM (Schmitz et al. 2011) (25.5 %/
15.5 %). The conservation with Pms and PlyCM is highest in
the region of the SH3_3 hypothetical domain near the C
terminus, with 44.8 % consensus/29.3 % identity between this
54 amino acid region in CP25L and the corresponding regions
in Pms and PlyCM. The region of the amidase_2 domain also
showed some homology to predicted endolysins from
podoviruses of C. perfringens (Volozhantsev et al. 2012); for
example, the CP25L sequence shows 66.9 % consensus/
57.4 % identity over the first 135 amino acids covering the
amidase_2 domain with the predicted lysin from ΦZP2.
Interestingly, when CP25L was analyzed by Blastp, the se-
quences showing the highest similarity had the amino acid
conservation concentrated in the center of the sequence, be-
tween the enzymatic and SH3 domains in an area without
homology to a functional domain (Fig. 1). These sequences
were all annotated as putative amidases from C. perfringens
sequenced genomes in the NCBI databases, and it is possible
that conservation of this area is relevant to the target cell wall.
Expression and activity of CP25L
CP25L was expressed in E. coli as a His-tagged protein,
giving a product of c. 45 kD which was visible in crude
extracts and bound a His-tag antibody (data not shown).
Crude protein extracts showed lytic activity when incubated
with C. perfringens cells (58.5±1.8 % drop in OD600 over
4 min when using 33 μg/ml protein), while lytic activity of the
crude protein extracts from empty vector control samples was
minimal over this period and similar to buffer controls; lysis of
cells which had not been frozen after harvest was slower
(12.4±0.1 %) but still resulted in complete lysis within
10 min (data not shown).
Ni-NTA columns were used to purify His-tagged CP25L
from E. coli cells to assess lytic activity and host range of the
endolysin (Fig. 2a). Strong lytic activity was shown by an
effective drop in the OD600 reading within 6 min of addition of
3, 33, or 100 μg/ml of Ni-NTA-purified protein to frozen cells
of C. perfringens (Fig. 2b). The speed of cell lysis obtained
with 3 μg/ml of protein was similar to that obtained with
33 μg/ml, the OD600 dropping from c. 0.65 to c. 0.13 in less
than 5 min. Lower concentrations gave slower lysis—0.3 μg/
ml gave a 9.1±0.1% drop in OD600 over 4 min comparedwith
79.5±1.4% using 3μg/ml, while 0.03μg/ml failed to produce
appreciable lysis. However, lysis from 100 μg/ml was slightly
slower than that from 33 μg/ml; this phenomenon of reduced
activity with higher concentrations has been observed previ-
ously (Mayer et al. 2010) and may be associated with precip-
itation of the protein at high concentrations. As noted with
other clostridial species (Mayer et al. 2008;Mayer et al. 2012),
slow gradual lysis of cells was also commonly observed in
buffer controls.
The Ni-NTA-purified CP25L was stable at 4 °C for several
months, and its activity was not affected by a 30-min incuba-
tion at 37 °C or 45 °C; however, treatment at 65 °C for 30min,
or 42 °C overnight, or a pasteurization treatment at 72 °C for
20 s all abolished lytic activity (data not shown). Stability at
room temperature was monitored over 3 weeks, the activity
remaining largely unchanged after 8 days compared with a
sample stored at 4 °C, but, after 15 and 22 days storage at
room temperature, the endolysin activity had reduced to c.
83 % and c. 62 % respectively, compared with the protein
samples stored at 4 °C (Fig. 3).
Lysis assays were performed to examine the activity of
CP25L when cells were suspended in broth media such as
BHI+C or CM (Fig. 2c). Lytic activity was observed when
cells were resuspended in BHI+C but was reduced in com-
parison to PBS; however, the lysis in CM, a complex medium
designed to simulate GI tract conditions, was more effective.
When tested under anaerobic conditions in BHI+C growth
medium, which allows rapid growth of C. perfringens, the
addition of endolysin to C. perfringens culture at the point of
cell inoculation resulted in a dramatic 5-log reduction in viable
cell counts compared with the culture not exposed to
endolysin (Fig. 4a). However, on continued culturing, the
pathogen was able to recover its population density. When
the lysin was added to the culture during the log phase, it
failed to reduce the bacterial count (Fig. 4b).
The host range of CP25L was tested using frozen cells of
C. perfringens strains and a variety of clostridial and non-
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clostridial species. All of the 25 C. perfringens strains tested
were sensitive to the endolysin, but the speed of lysis varied
greatly (Table 1). For some strains, the drop in turbidity was
immediate, while with others there was a lag of up to c. 20min
CP25L        ------------------------------MYINQSNIKFNGLRYGNDPNKIIIHNADATSCSVYDIDRW  40
EIA17471    ------------------------------MYINQSNIKFNGLNYGNNPNKIIIHNADHPNCSVYDVDRW  40
ZP_02633232 ----------------------------MNIKTDLTSVNYRNGRNGNSIDYIVCHFTGNQNDKASGNANY  42
ZP_02640305 ----------------------------MKINKRLSTTNVT--LNANNPKHIIIHETDNTSKGAGAETHC  40
ZP_02636955 -----MKIAVRGGHNFQAKGASALIDETIEDRKVKDSVILNLRKEGHEVLDVTPGNCDVNTDLRYGVNKA  65
ZP_02630819 MSKNIKKIAVRGGHNFQATGAVALIGETSEDRKVKDSVIVYLRQEGYQVLDVTPGNCDQITDLRYGVNKA  70
ZP_02953092 -----MKIAVRGGHNFQATGAAALIGETSEDRKVKDSVIECLRQEGHQVLDVTPGNCDQITDLRYGVNKA  65
CP25L       HKGNG--WSGIGYDYFIRKEGS---------VW-TGRPENAIGAHTIGQNSSSIGICLEGAFMREKPTRA  98






CP25L       QLNSLYELIADIRARR--GNLPVYGHKDFNN--------TDCPGINFPLEQFKNNSYRPTGG-EIVSDNG 157






CP25L        FYRSDEERTNATIVGEGNIEVLDKNCKVIENRYISSLDRVFVLGIYPASKYIEIIYPAGNEKYHAYISIE 227






CP25L        NYSRISFDYHMQYKNDNGVTYVWWDSEDVNVKEHNEELQANQKASPMYRVGKWLRVTFYRTDGTPSDGFV 297






CP25L        RYEGEQAVKFYEEEKIKEGIVKVNTYLNVRDSINGNIIGKVFNGEEVSIIWTKDGWYYIDYNTNHGKKRG 367






CP25L        YVSSKYVEEV- 377






Fig. 1 Alignment of the amino acid sequence of CP25L compared with
putative N-acetylmuramoyl-L-alanine amidases from C. perfringens ge-
nomes identified by Blastp analysis. Coloring of letters indicates degree
of amino acid conservation between sequences (black, 100 %, dark grey
80 %, light grey 60 %); lines above CP25L sequence indicate areas of
homology with the PGRP and amidase_2 domains (black line) or the
SH3_3 bacterial domain (grey)
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before lysis was detected. Sensitivity to the positive control
lysozyme was also variable, with some strains being insensi-
tive while others exhibited rapid lysis. There was no apparent
relationship between sensitivity to the CP25L lysin and to
lysozyme. In addition, CP25L also showed activity against
Clostridium bifermentans, Clostridium acetobutylicum,
Clostridium beijerinckii, Bacillus subtilis, and Bacillus cereus
cells (Table 1) but failed to cause lysis of a range of other
bacteria (data not shown, strains listed in Table 2).
L. johnsonii as an endolysin delivery vehicle
The cp25l gene was cloned into an expression and delivery
system which combined expression from the PnisA, in con-
junction with the chromosomally located signal transduction
nisRK genes, with a signal peptide to secrete the lysin. To
confirm lysin expression in this host, crude protein extracts
from L. johnsonii were used in turbidity reduction assays
(Fig. 5). This showed firstly that extracts from L. johnsonii
carrying the lysin expression construct (FI10744-L) had a lytic
activity that was absent from extracts of the empty vector
control (FI10744-V) and secondly that lytic activity from cells
induced with nisin was equivalent to that from uninduced
cells. This demonstrates that the nisRK-PnisA system produced
in L. johnsonii FI10744-L gives constitutive expression with-
out the requirement for nisin induction. Secretion of the
endolysin was assessed using L. johnsonii culture superna-
tants (Fig. 6a). The lytic activity associated with the concen-
trated supernatant was demonstrated in samples prepared from
cultures of FI10744-L grown either with or without nisin
induction, showing that the SLPmod signal peptide is effec-
tive for lysin secretion. Constitutive endolysin expression and
secretion was further demonstrated by growing colonies of L.
johnsonii on plates incorporating autoclaved C. perfringens
cells, with clear development of zones of lysis around colonies
expressing the lysin (Fig. 6b).
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Fig. 2 Expression of CP25L in E. coli. a SDS-PAGE analysis of prod-
ucts from Ni-NTA column purification. Lanes 1, SeeBlue Plus2 marker,
2, cell lysate, 3, column flow through, 4–5 column washes, 6–8 succes-
sive 1 ml column eluates. Lanes contain 3.25 μl samples. b, c Lytic
activity of Ni-NTA-purified protein on C. perfringens showing the effect
of protein concentration (b) and lysis medium (c). b Closed square,
100 μg/ml; open square, 33 μg/ml; small closed square, 3 μg/ml; closed
triangle, 0.3 μg/ml; and open triangle, 0.03 μg/ml of CP25L compared
with buffer control (EB, closed circle). c Cells were resuspended in PBS
(closed circle), BHI+C, (closed triangle), or CM (closed square) and
incubated with 33 μg/ml CP25L (closed symbols) or EB (open symbols).




































Fig. 3 CP25L stability. Endolysin activity was measured in turbidity
reduction assays using 33 μg/ml Ni-NTA-purified protein. Results repre-
sent the activity of samples stored at room temperature as a percentage of
the activity of endolysin stored at 4 °C assayed at the same time; activity
was calculated as the percent decrease in OD600 over 4 min of linear lysis






































Fig. 4 Viability assays under anaerobic conditions to examine the effect
of 33 μg/ml Ni-NTA-purified CP25L (black bars) on the viability of C.
perfringens in comparison with the buffer control (white bars). Endolysin
was added to the media either at point of inoculation (0 h) (a), or during
the early exponential phase (OD600 0.3, 3.5 h) (b)
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Discussion
C. perfringens is widely distributed in the intestine of animals,
especially poultry, and can be pathogenic to the host. It is
responsible both for severe infections and important economic
losses (Lee et al. 2011; Scallan et al. 2011); targeting the
pathogen in poultry will have impacts not just on poultry
welfare and production but also on carriage in the food chain
and the incidence of human infections. In this study, we have
examined the ability of a novel endolysin to killC. perfringens
cells and demonstrated endolysin delivery by a probiotic strain
of L. johnsonii.
The gene for CP25L is located within a prophage which
can be released as a bacteriophage from the C. perfringens
chromosome (Gervasi et al. 2013). In common with three
other endolysins which have been demonstrated to show
activity against C. perfringens, it is predicted to be an amidase
(Simmons et al. 2010; Zimmer et al. 2002). A number of
prophage lysin-like enzymes found in the genomes of C.
perfringens contain an amidase domain, and the presence of
an SH3 domain is also very prevalent in these proteins
(Schmitz et al. 2011). In CP25L, the predicted SH3_3 domain
is present in the C-terminal region commonly associated with
endolysin specificity (Fischetti 2010; Schmelcher et al. 2012).
The C-terminal and the central region between the amidase
domain and the SH3_3 domain showed high similarity to
other putative amidases from C. perfringens, and it will be
interesting to investigate whether these regions are associated
with recognition of the C. perfringens cell wall.
When expressed from E. coli, CP25L showed a potent lytic
activity against C. perfringens NCTC 3110, a type B strain
and was also active against all 24 other C. perfringens strains
tested. However, activity varied widely between strains, even
between two strains of the same type A (NCTC 8238 and
8239). Although sensitivity to the lysozyme positive control
also varied to a lesser extent between strains, there was no
relationship between the speed of lysis with lysozyme and that
with CP25L. This large difference in activity between strains
was also found with the amidase endolysins Ply3626,
PlyCP39O, and PlyCP26F and the glucosyl hydrolase
endolysins SM101 and PlyCM (Nariya et al. 2011; Schmitz
et al. 2011; Simmons et al. 2010; Zimmer et al. 2002), al-
though CP25L shows a slightly broader host range than most
of these lysins. The sensitivity of other selected clostridial and
Bacillus species might indicate shared binding targets in the
cell walls of these organisms.
The ability to lyse cells in complex media at physiologi-
cally relevant pH values suggests that the endolysin might be
able to function in GI tract conditions, without causing collat-
eral damage to the normal microflora. However, as demon-
strated in small cultures, despite initial evidence of control, the

















Fig. 5 Endolysin expression in L. johnsonii. Frozen cells of C.
perfringens were incubated with 33 μg/ml crude protein extracts from
L. johnsonii FI10744-L (filled square) or FI10744-V (filled triangle), or
EB (open circle). Filled symbols were from cultures induced with nisin;
open symbols had no exposure to nisin. Results are the mean of duplicate
assays±standard deviation
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Fig. 6 Endolysin delivery from L. johnsonii. a Plate assay showing lysis
from crude protein extracts (1–4) and concentrated supernatants (5–7,
20× concentrated; 9–12, 166× concentrated) from L. johnsonii FI10744-L
induced with nisin (1, 5, 9) or uninduced (3, 7, 11), L. johnsonii FI10744-
V induced with nisin (2, 6, 10) or uninduced (4, 12); 8, EB control. b Lytic
zones produced by growing colonies of FI10744-L (L) compared with
control FI10744-V (V) on media incorporating autoclaved C. perfringens
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treatment in a medium which favored rapid growth, while
addition to a rapidly growing culture was ineffective. It is
possible that the lysin remains attached to the cell walls of
lysed cells, leading to a depletion in concentration and
allowing rapidly growing cells to outstrip the lytic activity.
Control might be more effective under less optimal growth
conditions, such as in the competitive environment of the GI
tract, and the lysin was shown to function in a complex
medium that permits the growth of gut bacteria in simulated
colon conditions with pH 6 and incubation temperature of
37 °C. However, survival of the lysin and contact with the C.
perfringens target are further hurdles to overcome in the GI
tract. Together with the finding that the lytic activity is not
stable after prolonged incubation at 42 °C, these results indi-
cate that a continuous high production of protein prior to
infection would be required for pathogen control. This would
be a feasible proposition in an environment where the
endolysin was delivered to the gut via a colonizing probiotic.
L. johnsonii FI9785 was previously shown to reduce colo-
nization and shedding of C. perfringens in chickens after a
single oral dose (La Ragione et al. 2004), making it an ideal
tool for preventative treatment. The use of a delivery system
incorporating the signal peptide SLPmod, which has previ-
ously been demonstrated to be effective in the delivery of
interleukin-12 to the mouse gut by L. lactis (Fernandez et al.
2009), gave successful production and secretion of a function-
al enzyme, as demonstrated by the lysis assays. Furthermore,
the combination of the nisin A promoter and the chromosom-
ally located signal transduction genes gave constitutive pro-
duction without the need for nisin induction, which is of great
potential benefit for use in animals. Production in L. johnsonii
was lower than that in E. coli, and this is an area which may
benefit from improvement. Another possibility is co-delivery
or co-application with other antimicrobials—the combination
of a phage endolysin with nisin achieved a strong synergistic
effect against Staphylococcus aureus (Garcia et al. 2010), and
the ability of lactobacilli to produce a range of bacteriocins, in
addition to their other probiotic properties (Lebeer et al. 2008),
make them valuable candidates as vehicles to deliver specific
antimicrobials to gut communities. This preliminary study
indicates that either large numbers of probiotic bacteria com-
bined with high delivery rates and high activity of one or more
antimicrobial or somemethod of attracting the bacterium to its
target will be necessary for effective control.
The probiotic L. johnsonii has the capability to exclude C.
perfringens from the GI tract of poultry birds. In this study, we
have demonstrated its ability to express a biologically active
anti-C. perfringens endolysin, indicating that the engineered
strain has the potential to be an even more effective control
agent for this pathogen. Future work will focus on the efficacy
of the CP25L-secreting L. johnsonii FI10744-L strain in con-
trollingC. perfringens in a GI tract environment, on its own or
in co-application with other antimicrobials.
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